TRPV1 Activation is Required for Hypertonicity-stimulated Inflammatory Cytokine Release in Human Corneal Epithelial Cells
Overview
Affiliations
Purpose: To determine whether hypertonic stress promotes increases in inflammatory cytokine release through transient receptor potential vanilloid channel type 1 (TRPV1) signaling pathway activation in human corneal epithelial cells (HCECs).
Methods: Hyperosmotic medium was prepared by supplementing isotonic Ringers solution with sucrose. Ca2+ signaling was measured in fura2-AM-loaded HCECs using a single-cell fluorescence imaging system. Western blot analysis evaluated the phosphorylation status of EGFR, ERK, p38 MAPK, and nuclear factor (NF)-κB. ELISA assessed the effect of TRPV1 activation on the release of IL-6 and IL-8.
Results: A 450 mOsm hypertonic stress elicited 2-fold Ca2+ transients that were suppressed by the TRPV1-selective antagonists capsazepine and JYL 1421. Such transients were enhanced by PGE2. Hypertonicity-induced EGF receptor (EGFR) transactivation was suppressed by preincubating HCECs with capsazepine, matrix metalloproteinase 1 (MMP1) inhibitor TIMP-1, broad-spectrum MMP inhibitor GM 6001, heparin-bound (HB)-EGF inhibitor CRM 197, or EGFR inhibitor AG 1478. ERK and p38 MAPK and NF-κB activation after EGFR transactivation occurred in tonicity and in a time-dependent manner. Hypertonicity-induced increases in IL-6 and IL-8 releases were suppressed by exposure to capsazepine, AG 1478, ERK inhibitor PD 98059, p38 inhibitor SB 203580, or NF-κB inhibitor PDTC.
Conclusions: Hypertonic stress-elicited TRPV1 channel stimulation mediates increases in a proinflammatory cytokine IL-6 and a chemoattractant IL-8 by eliciting EGFR transactivation, MAPK, and NF-κB activation. Selective drug modulation of either TRPV1 activity or its signaling mediators may yield a novel approach to suppressing inflammatory responses occurring in dry eye syndrome.
Role of Chinese Medicine Monomers in Dry Eye Disease: Breaking the Vicious Cycle of Inflammation.
Hu Z, Chen X, Hu Q, Zou M, Liu Z Pharmacol Res Perspect. 2025; 13(2):e70077.
PMID: 39979080 PMC: 11842162. DOI: 10.1002/prp2.70077.
Ion Channels as Potential Drug Targets in Dry Eye Disease and Their Clinical Relevance: A Review.
Harrell C, Volarevic V Cells. 2024; 13(23).
PMID: 39682765 PMC: 11639998. DOI: 10.3390/cells13232017.
Li H, Zhang Y, Chen Y, Zhu R, Zou W, Chen H Mol Med Rep. 2024; 30(6).
PMID: 39370807 PMC: 11450431. DOI: 10.3892/mmr.2024.13337.
Harrell C, Feulner L, Djonov V, Pavlovic D, Volarevic V Cells. 2023; 12(23).
PMID: 38067183 PMC: 10706334. DOI: 10.3390/cells12232755.
Lucius A, Chhatwal S, Valtink M, Reinach P, Li A, Pleyer U Int J Mol Sci. 2023; 24(14).
PMID: 37511574 PMC: 10380586. DOI: 10.3390/ijms241411815.